On the other hand, Molnupavir is a close cousin of Remdesivir. However Remdesivir cannot be taken orally. This was the goal of of the development of Molnupavir. This Nature article does a very good job of describing the pharmacokinetics/pharmacodynamics of Molnupavir:
"Similar to other nucleoside analogs, molnupiravir targets the SARS-CoV-2 RNA-dependent RNA polymerase (RdRp), which mediates replication and transcription of the coronavirus genome. Viral RdRps are proven effective targets for inhibition, with several licensed nucleoside analogs that are used therapeutically. Indeed, the only currently clinically approved antiviral used for the treatment of COVID-19 is remdesivir (Veklury), which targets the RdRp. Similar to remdesivir, molnupiravir has been re-investigated as a coronavirus antiviral agent that leads to increased frequency of G-to-A and C-to-U transition mutations."
Some highlights from the video and referenced comparison article
https://austinpublishinggroup.com/pharmacology-therapeutics/fulltext/ajpt-v9-id1149.pdf
Tmax (the time it takes to get to maximum plasma concentrations)
Molnupiravir : 1-1.75 hours
Ivermectin : 4-6 hours
Half life
Molnupiravir : 7 hours
Ivermectin : 81-91 hours (less than this according to some other researches, but still far better than Molnupiravir. Besides Ivermectin has the ability to accumulate in the lungs, which is very important for treating Sars-Cov-2 infection)
Inhibation of cytokine production and inflammation
Molnupiravir : Not known yet
Ivermectin : Effective
Total Cost/Price per treatment
Molnupiravir : 700 USD
Ivermectin : 0.53 USD
Safety/Adverse events
Molnupiravir : Unknown yet
Ivermectin : Very low number of adverse events (3.7 billion doses have been given to humans so far and only 5693 AE records retrieved. For comparison the number for ibuprofen is 165.479
More in the video above